After intranasal administration of PACAP1-38 for three months in AD transgenic mice, APP processing shifted toward the non-amyloidogenic pathway and, in addition, brain-derived neurotrophic factor (BDNF) expression also increased as another beneficial effect of PACAP1-38 inhalation. The gene discussed is BDNF; the disease is Alzheimer disease.